Meta’s AI organization underwent tremendous change in 2025. After the disappointing debut of its flagship Llama 4 model, ...

RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground.

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral ...

The book takes a close look at how knowledge spreads among people and throughout societies. For example: “The Emperor’s New ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...